(KOD) – Trader Talk
-
Kodiak Sciences (KOD) Plunges Over 70% as KSI-301 Fails to Meet Primary Efficacy Endpoint
-
Kodiak (KOD) Reiterated at Buy by Truist Securities, Analyst Believes wAMD Trial Will be Successful, Models Peak Sales of $2.7B
Back to KOD Stock Lookup
